Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 43

1.

Is There a Role for DAT-SPECT Imaging in a Specialty Movement Disorders Practice?

Bega D, Gonzalez-Latapi P, Zadikoff C, Spies W, Simuni T.

Neurodegener Dis. 2015;15(2):81-6. doi: 10.1159/000370116. Epub 2015 Jan 15.

PMID:
25592727
2.

Long-term safety and maintenance of efficacy of levodopa-carbidopa intestinal gel: an open-label extension of the double-blind pivotal study in advanced Parkinson's disease patients.

Slevin JT, Fernandez HH, Zadikoff C, Hall C, Eaton S, Dubow J, Chatamra K, Benesh J.

J Parkinsons Dis. 2015;5(1):165-74. doi: 10.3233/JPD-140456.

PMID:
25588353
3.

Complementary & alternative management of Parkinson's disease: an evidence-based review of eastern influenced practices.

Bega D, Zadikoff C.

J Mov Disord. 2014 Oct;7(2):57-66. doi: 10.14802/jmd.14009. Epub 2014 Oct 30. Review.

4.

A review of the clinical evidence for complementary and alternative therapies in Parkinson's disease.

Bega D, Gonzalez-Latapi P, Zadikoff C, Simuni T.

Curr Treat Options Neurol. 2014 Oct;16(10):314. doi: 10.1007/s11940-014-0314-5.

PMID:
25143234
5.

The development and implementation of the Chicago public schools emergency EpiPen® policy.

Zadikoff EH, Whyte SA, Desantiago-Cardenas L, Harvey-Gintoft B, Gupta RS.

J Sch Health. 2014 May;84(5):342-7. doi: 10.1111/josh.12147.

PMID:
24707929
6.

A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit.

Parkinson Study Group QE3 Investigators, Beal MF, Oakes D, Shoulson I, Henchcliffe C, Galpern WR, Haas R, Juncos JL, Nutt JG, Voss TS, Ravina B, Shults CM, Helles K, Snively V, Lew MF, Griebner B, Watts A, Gao S, Pourcher E, Bond L, Kompoliti K, Agarwal P, Sia C, Jog M, Cole L, Sultana M, Kurlan R, Richard I, Deeley C, Waters CH, Figueroa A, Arkun A, Brodsky M, Ondo WG, Hunter CB, Jimenez-Shahed J, Palao A, Miyasaki JM, So J, Tetrud J, Reys L, Smith K, Singer C, Blenke A, Russell DS, Cotto C, Friedman JH, Lannon M, Zhang L, Drasby E, Kumar R, Subramanian T, Ford DS, Grimes DA, Cote D, Conway J, Siderowf AD, Evatt ML, Sommerfeld B, Lieberman AN, Okun MS, Rodriguez RL, Merritt S, Swartz CL, Martin WR, King P, Stover N, Guthrie S, Watts RL, Ahmed A, Fernandez HH, Winters A, Mari Z, Dawson TM, Dunlop B, Feigin AS, Shannon B, Nirenberg MJ, Ogg M, Ellias SA, Thomas CA, Frei K, Bodis-Wollner I, Glazman S, Mayer T, Hauser RA, Pahwa R, Langhammer A, Ranawaya R, Derwent L, Sethi KD, Farrow B, Prakash R, Litvan I, Robinson A, Sahay A, Gartner M, Hinson VK, Markind S, Pelikan M, Perlmutter JS, Hartlein J, Molho E, Evans S, Adler CH, Duffy A, Lind M, Elmer L, Davis K, Spears J, Wilson S, Leehey MA, Hermanowicz N, Niswonger S, Shill HA, Obradov S, Rajput A, Cowper M, Lessig S, Song D, Fontaine D, Zadikoff C, Williams K, Blindauer KA, Bergholte J, Propsom CS, Stacy MA, Field J, Mihaila D, Chilton M, Uc EY, Sieren J, Simon DK, Kraics L, Silver A, Boyd JT, Hamill RW, Ingvoldstad C, Young J, Thomas K, Kostyk SK, Wojcieszek J, Pfeiffer RF, Panisset M, Beland M, Reich SG, Cines M, Zappala N, Rivest J, Zweig R, Lumina LP, Hilliard CL, Grill S, Kellermann M, Tuite P, Rolandelli S, Kang UJ, Young J, Rao J, Cook MM, Severt L, Boyar K.

JAMA Neurol. 2014 May;71(5):543-52. doi: 10.1001/jamaneurol.2014.131.

PMID:
24664227
7.

Circadian melatonin rhythm and excessive daytime sleepiness in Parkinson disease.

Videnovic A, Noble C, Reid KJ, Peng J, Turek FW, Marconi A, Rademaker AW, Simuni T, Zadikoff C, Zee PC.

JAMA Neurol. 2014 Apr;71(4):463-9. doi: 10.1001/jamaneurol.2013.6239.

8.

Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study.

Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, Vanagunas A, Othman AA, Widnell KL, Robieson WZ, Pritchett Y, Chatamra K, Benesh J, Lenz RA, Antonini A; LCIG Horizon Study Group.

Lancet Neurol. 2014 Feb;13(2):141-9. doi: 10.1016/S1474-4422(13)70293-X. Epub 2013 Dec 20. Erratum in: Lancet Neurol. 2014 Mar;13(3):240.

PMID:
24361112
9.

Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD).

Parkinson Study Group.

Mov Disord. 2013 Nov;28(13):1823-31. doi: 10.1002/mds.25639. Epub 2013 Sep 30.

PMID:
24123224
10.

Matrix metalloproteinase levels in early HIV infection and relation to in vivo brain status.

Li S, Wu Y, Keating SM, Du H, Sammet CL, Zadikoff C, Mahadevia R, Epstein LG, Ragin AB.

J Neurovirol. 2013 Oct;19(5):452-60. doi: 10.1007/s13365-013-0197-3. Epub 2013 Aug 27.

11.

Deep brain stimulation improves movement amplitude but not hastening of repetitive finger movements.

Stegemöller EL, Zadikoff C, Rosenow JM, Mackinnon CD.

Neurosci Lett. 2013 Sep 27;552:135-9. doi: 10.1016/j.neulet.2013.07.056. Epub 2013 Aug 11.

PMID:
23941889
12.

Impact of mild cognitive impairment on health-related quality of life in Parkinson's disease.

Reginold W, Duff-Canning S, Meaney C, Armstrong MJ, Fox S, Rothberg B, Zadikoff C, Kennedy N, Gill D, Eslinger P, Marshall F, Mapstone M, Chou KL, Persad C, Litvan I, Mast B, Tang-Wai D, Lang AE, Marras C.

Dement Geriatr Cogn Disord. 2013;36(1-2):67-75. doi: 10.1159/000350032. Epub 2013 Jun 15.

PMID:
23774742
13.

Implicit perceptual-motor skill learning in mild cognitive impairment and Parkinson's disease.

Gobel EW, Blomeke K, Zadikoff C, Simuni T, Weintraub S, Reber PJ.

Neuropsychology. 2013 May;27(3):314-21. doi: 10.1037/a0032305.

14.

Clinical Reasoning: a woman with rapidly progressive apraxia.

Pressman P, Bigio EH, Gitelman D, Zadikoff C.

Neurology. 2013 Apr 9;80(15):e162-5. doi: 10.1212/WNL.0b013e31828c2eb8. No abstract available.

15.

Measuring mild cognitive impairment in patients with Parkinson's disease.

Marras C, Armstrong MJ, Meaney CA, Fox S, Rothberg B, Reginold W, Tang-Wai DF, Gill D, Eslinger PJ, Zadikoff C, Kennedy N, Marshall FJ, Mapstone M, Chou KL, Persad C, Litvan I, Mast BT, Gerstenecker AT, Weintraub S, Duff-Canning S.

Mov Disord. 2013 May;28(5):626-33. doi: 10.1002/mds.25426. Epub 2013 Mar 20.

PMID:
23520128
16.

Amantadine for freezing of gait in patients with Parkinson disease.

Malkani R, Zadikoff C, Melen O, Videnovic A, Borushko E, Simuni T.

Clin Neuropharmacol. 2012 Nov-Dec;35(6):266-8. doi: 10.1097/WNF.0b013e31826e3406.

18.

The meaning of a "hippo" response on the Montreal Cognitive Assessment in Parkinson's disease.

Armstrong MJ, Duff-Canning S, Tang-Wai DF, Fox S, Zadikoff C, Kennedy N, Gill D, Eslinger PJ, Mapstone M, Chou KL, Persad C, Litvan I, Mast BT, Marras C.

Parkinsonism Relat Disord. 2013 Apr;19(4):463-5. doi: 10.1016/j.parkreldis.2012.09.005. Epub 2012 Oct 1. No abstract available.

PMID:
23036511
19.

Roles of Education and IQ in Cognitive Reserve in Parkinson's Disease-Mild Cognitive Impairment.

Armstrong MJ, Naglie G, Duff-Canning S, Meaney C, Gill D, Eslinger PJ, Zadikoff C, Mapstone M, Chou KL, Persad C, Litvan I, Mast BT, Fox S, Tang-Wai DF, Marras C.

Dement Geriatr Cogn Dis Extra. 2012 Jan;2(1):343-52. doi: 10.1159/000341782. Epub 2012 Aug 22.

20.

The pill questionnaire in a nondemented Parkinson's disease population.

Reginold W, Armstrong MJ, Duff-Canning S, Lang A, Tang-Wai D, Fox S, Rothberg B, Zadikoff C, Kennedy N, Gill D, Eslinger P, Mapstone M, Chou K, Persad C, Litvan I, Mast B, Marras C.

Mov Disord. 2012 Sep 1;27(10):1308-11. doi: 10.1002/mds.25124. Epub 2012 Aug 1.

PMID:
22865587
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk